---
title: "Top 10 US Stock Gainers (10.27)"
description: "Strive(ASST) rose 49.09%, with a trading turnover 1.6 Billion USD, and a year-to-date rose 234.4%. Grupo Superbielle SA(SUPV) rose 47.99%, with a trading turnover 163.1 Million USD, and a year-to-date"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262964960.md"
published_at: "2025-10-27T22:01:01.000Z"
---

# Top 10 US Stock Gainers (10.27)

> Strive(ASST) rose 49.09%, with a trading turnover 1.6 Billion USD, and a year-to-date rose 234.4%. Grupo Superbielle SA(SUPV) rose 47.99%, with a trading turnover 163.1 Million USD, and a year-to-date fell 33.2%. Avidity Biosciences(RNA) rose 42.42%, with a trading turnover 4.9 Billion USD, and a year-to-date rose 140.7%.

NASDAQ Composite Index has rose 1.86%, with a year-to-date rose 22.4%; S&P 500 has rose 1.23%, with a year-to-date rose 16.9%; Dow Jones Industrial Average has rose 0.71%, with a year-to-date rose 11.8%.

Strive(ASST) rose 49.09%, with a trading turnover 1.6 Billion USD, and a year-to-date rose 234.4%.

Grupo Superbielle SA(SUPV) rose 47.99%, with a trading turnover 163.1 Million USD, and a year-to-date fell 33.2%.

Avidity Biosciences(RNA) rose 42.42%, with a trading turnover 4.9 Billion USD, and a year-to-date rose 140.7%.

### Related Stocks

- [ASST.US - Strive](https://longbridge.com/en/quote/ASST.US.md)
- [SUPV.US - Grupo Superbielle SA](https://longbridge.com/en/quote/SUPV.US.md)
- [RNA.US - Avidity Biosciences](https://longbridge.com/en/quote/RNA.US.md)
- [DYN.US - Dyne Therapeutics](https://longbridge.com/en/quote/DYN.US.md)
- [BBAR.US - BBVA Argentina SA](https://longbridge.com/en/quote/BBAR.US.md)
- [GGAL.US - Grupo Financiero Galicia](https://longbridge.com/en/quote/GGAL.US.md)
- [BMA.US - Banco Macro Bansud SA](https://longbridge.com/en/quote/BMA.US.md)
- [TGS.US - Transportadora De Gas](https://longbridge.com/en/quote/TGS.US.md)
- [ZBIO.US - Zenas Biopharma](https://longbridge.com/en/quote/ZBIO.US.md)
- [YPF.US - YPF Sociedad Anonima](https://longbridge.com/en/quote/YPF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Assessing Zenas BioPharma (ZBIO) Valuation After Positive MoonStone Phase 2 Results In Multiple Sclerosis | Zenas BioPharma (ZBIO) has gained attention following positive Phase 2 MoonStone trial results for obexelimab in relapsi | [Link](https://longbridge.com/en/news/275927617.md) |
| Zenas BioPharma (NASDAQ:ZBIO) Director Buys $109,657.60 in Stock | Zenas BioPharma Director Patricia Allen purchased 4,160 shares at $26.36 each, totaling $109,657.60, increasing her owne | [Link](https://longbridge.com/en/news/275954731.md) |
| TGS startet Engagement-9-Seismikprojekt im Golf von Amerika | TGS ASA, in collaboration with SLB, has announced the launch of the "Engagement Phase 9" seismic project in the Gulf of  | [Link](https://longbridge.com/en/news/275408284.md) |
| Macro Bank (NYSE:BMA) Downgraded by Zacks Research to "Strong Sell" | Macro Bank (NYSE:BMA) has been downgraded by Zacks Research from a "hold" to a "strong sell" rating. Other analysts have | [Link](https://longbridge.com/en/news/275609822.md) |
| Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions | Zenas Biopharma Inc. reported positive results from its Phase 2 MoonStone trial of obexelimab for Relapsing Multiple Scl | [Link](https://longbridge.com/en/news/275313739.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.